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hemodialysis patient with diabetes mellitus:
a case report and literature review
Taro Horino*, Yoshiko Shimamura, Koji Ogata, Kosuke Inoue and Yoshio TeradaAbstract
Background: Kocuria kristinae is an aerobic Gram-positive coccus that is considered ubiquitous and non-
pathogenic in healthy individuals. Furthermore, only 27 reports have described cases of critical infections with this
microorganism, which is notoriously difficult to identify.
Case presentation: We report the case of a 61-year-old male hemodialysis patient with diabetes mellitus, who
developed severe septic arthritis that was associated with infectious endocarditis, which was identified using
18F-fluorodeoxyglucose positron-emission tomography/computed tomography (FDG-PET-CT). K. kristinae was
identified in two separate blood cultures. The patient recovered immediately after being treated using piperacillin
followed by ampicillin/sulbactam and gentamicin.
Conclusions: To the best of our knowledge, this is the first case of K. kristinae septic arthritis associated with
infectious endocarditis in a hemodialysis patient with diabetes mellitus. We suggest that physicians consider the
pathogenic potential of K. kristinae, which can cause fatal infections, such as septic arthritis and infectious
endocarditis, in immunocompromised patients. FDG-PET-CT is a useful and safe diagnostic tool for determining the
cause of inflammatory disease in dialysis patients.
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In Japan, the number of patients with diabetes is increas-
ing every year, as is the rate of renal replacement therapy
(RRT) for treating diabetic nephropathy. Both end-stage
renal disease (ESRD) and diabetes mellitus are severe
immunocompromised states, and dialysis patients are
prone to infectious complications. Furthermore, we be-
lieve that patients with diabetes mellitus are predisposed
to invasive infections. Therefore, we describe the case of
a hemodialysis patient who had a wound infection and
bacteremia with Kocuria kristinae, which is a micro-
organism that is considered non-pathogenic in healthy
individuals. In addition, we provide a review of case re-
ports regarding K. kristinae infections in humans.* Correspondence: horinott@yahoo.co.jp
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A 61-year-old male hemodialysis patient with a history
of diabetes mellitus and polyarthralgia was referred to
our hospital. Two months before the referral, the patient
had arthralgia of the right knee, which exhibited swell-
ing, tenderness, and restricted motion. The patient sub-
sequently experienced severe polyarthralgia that
involved both shoulders, wrists, hip joints, foot joints,
and the left knee joint, as well as rapidly progressing se-
vere lumbago. At the admission, his temperature was
36.6 °C. A physical examination revealed swelling and
warmth in all joints that the patient identified as being
painful. The laboratory test results are shown in Table 1.
A chest radiograph revealed mild cardiomegaly without
other remarkable findings. Joint radiographs revealed no
deformities. Magnetic resonance imaging (MRI) of the
left hip joint revealed high-intensity lesions surroundingis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Laboratory data at admission
CBC (normal range) Blood chemistry Tumor markers Blood culture
RBC (400–552) 239 × 104/mm3 FBS (70–110) 179 mg/dL CEA (<3.4) 0.8 ng/mL Kocuria kristinae (+)
Hb (13.2–17.2) 6.9 g/dL Alp (104–338) 501 U/L CA19-9 (<37) 2.8 U/mL Antimicrobial susceptibilities (MIC) μg/mL
Ht (40.4–51.1) 21.9 % γ-GTP (5–70) 41 U/L Infection Penicillin 0.12
Plt (14.8–33.9) 46.8 × 104/mm3 t-Bil (0.2–1.2) 0.3 mg/dL HBs Ag (−) Oxacillin ≤2.0
WBC (3.6–9.6) 5.6 × 103/mm3 d-Bil (0–0.4) 0.0 mg/dL HCV Ab (−) Ampicillin ≤0.25
neu 73.0 % ChE (168–470) 123 U/L HTLV-I Ab (−) Cefazolin ≤8.0
lym 8.0 % ALT (8–42) 24 U/L EBV Cefotaxime ≤8.0
mon 13.0 % AST (13–33) 37 U/L VCA-IgG ×640 cefepime ≤8.0
eos 6.0 % LDH (119–229) 125 U/L VCA-IgM ×<10 Cefotiam ≤8.0
bas 0.0 % CPK (62–287) 10 U/L EBNA ×20 Cefpirome ≤8.0
aty-ly 0.0 % Crn (0.6–1.1) 10.3 mg/dL Mumps (−) Cefozopran ≤8.0
Electrolytes BUN (8–20) 52 mg/dL Herpes zoster (−) Cefmetazole ≤16.0
Na (136–145) 137 mmol/L UA (3.4–7.8) 8.5 mg/dL Parvovirus B19 (−) Cefdinir ≤1.0
K (3.4–4.5) 4.4 mmol/L Amy (37–125) 71 U/L Syphilis (−) Cefditoren ≤1.0
Cl (100–108) 99 mmol/L TG (30–150) 106 mg/dL QFT (−) Flomoxef ≤8.0
Ca (8.7–11.0) 10.2 mg/dL H-Chol (>40) 17 mg/dL Candida Ab (−) Imipenem/cilastatin ≤4.0
P (2.5–4.5) 4.7 mg/dL L-Chol (<140) 61 mg/dL β-D-glucan (−) Meropenem ≤4.0
Mg (1.8–2.4) 2.5 mg/dL Serological examinations Chlamydia trachomatis Amoxicillin ≤4.0
Proteinogram CRP (<0.3) 35.5 mg/dL IgG (−) Gentamicin ≤4.0
TP (6.7–8.1) 7.1 g/dL SAA (<8.0) 1843.9 mg/mL IgA (−) Amikacin ≤16.0
Alb (3.9–4.9) 2.6 g/dL MMP-3 (36.9–121.0) 586.4 ng/mL Chlamydia pneumoniae Arbekacin ≤4.0
Glb 4.5 g/dL CH50 (30–45) 47.0 U/mL IgG (−) Erythromycin ≤0.5
α1 11.2 % C3 (65–135) 131.5 mg/dL IgA (−) Clarithromycin ≤2.0
α2 16.6 % C4 (13–35) 31.7 mg/dL Synovial fluid Clindamycin ≤0.5
β 10.7 % ANA (−) Glossly purulent material Minocycline ≤4.0
γ 34.3 % ds-DNA Ab (−) WBC 13,200 × 103/mm3 Linezolid ≤2.0
IgG (870–1700) 2519 mg/dL SSA Ab (−) neu 95.0 % Vancomycin ≤2.0
IgA (110–410) 497 mg/dL SSB Ab (−) pla 5.0 % Teicoplanin ≤8.0












Table 1 Laboratory data at admission (Continued)
M-protein (−) ACPA (−) Culture (−) Levofloxacin ≤1.0
HbA1c (4.6–6.2) 7.9 % MPO-ANCA (−) Sulfamethoxazole/trimethoprim ≤2.0
ESR (<20) >140 mm/h PR3-ANCA (−) Rifampicin ≤1.0
Abbreviations: CBC complete blood cell count, RBC red blood cell count, Hb hemoglobin, Ht hematocrit, Plt platelet, ESR erythrocyte sedimentation rate, WBC white blood cell count, neu neutrophils, lym lymphocytes,
mon monocytes, eoseosinophils, bas basophils, aty-ly atypical lymphocytes, Na sodium, K potassium, Cl chlorine, Ca calcium, P phosphorus, Mg magnesium, TP total protein, Alb albumin, Glb globulin, IgG
immunoglobulin G, IgA immunoglobulin A, IgM immunoglobulin M, FBS fasting blood sugar, Alp alkaline phosphatase, γ-GTP γ-glutamyltransferase, t-Bil total bilirubin, d-Bil direct bilirubin, ChE cholinesterase, ALT
alanine transaminase, AST aspartate aminotransferase, LDH lactate dehydrogenase, CPK creatine phosphokinase, Crn creatinine, BUN blood urea nitrogen, UA uric acid, Amy amylase, TG triglyceride, H-Chol high-density
lipoprotein cholesterol,
L-Chol low-density lipoprotein cholesterol, CRP C-reactive protein, SAA serum amyloid A, MMP-3 matrix metalloproteinase-3, CH50 complement activity, C3 complement 3, C4 complement 4, ANA antinuclear antibody,
SSA Ab anti-SS-A/Ro antibody,SSB Ab anti-SS-B/La antibody, RF rheumatoid factor, ACPA anti-cyclic citrullinated peptide antibody, MPO-ANCA myeloperoxidase-anti-neutrophil cytoplasmic antibody, PR3-ANCA serine
proteinase3-anti-neutrophil cytoplasmic antibody, HBs Ab hepatitis B surface antigen, HCV Ab hepatitis C virus antibody, HTLV-I Ab human T-lymphotropic virus type 1 antibody,pla plasma cell, EBV Epstein-Barr virus,












Fig. 1 The magnetic resonance imaging findings. The magnetic resonance findings from the left hip joint reveal high-intensity lesions (white
arrows) surrounding the head of the femoral bone in the T2-weighted image (right panel)
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(Fig. 1).18F-fluorodeoxyglucose positron-emission tom-
ography/computed tomography (FDG-PET-CT) re-
vealed short segments of increased FDG uptake
within the shoulders, wrists, hip joints, knees, and
foot joints (Fig. 2). We had performed arthrocentesis
at the admission, and an aspiration specimen from
the right knee joint yielded grossly purulent material.
Synovial fluid white cell counts were 13,200/mm3,
with 95 % polymorphonuclear leukocytes and 5 %Fig. 2 The 18F-fluorodeoxyglucose positron-emission tomography/comput
tomography/computed tomography reveals short segments of increased fl
hip joints, knees, and foot jointsmonomorphonuclear leukocytes. Although the syn-
ovial fluid culture was negative, clusters of Gram-
positive cocci were isolated from a blood specimen
that was taken at the admission. Two blood cultures
were both positive for K. kristinae, and these results
were confirmed using the Vitek 2 system. The isolate
was sensitive to all tested antibiotics (Table 1). We
started treatment using intravenous piperacillin (2 g
once per day), and the polyarthritis immediately im-
proved. After 14 days of antibiotic treatment, theed tomography findings. 18F-fluorodeoxyglucose positron-emission
uorodeoxyglucose uptake (white arrows) within the shoulders, wrists,
Fig. 3 The echocardiography findings. (Left panel) Echocardiography reveals no remarkable findings at 2 years before the presentation. (Right
panel) Echocardiography at 1 month after the admission reveals mitral valve vegetation
Horino et al. Renal Replacement Therapy  (2016) 2:32 Page 5 of 9patient’s C-reactive protein levels were 0.8 mg/dL and
the other laboratory data were normalized.
Electrocardiography detected no remarkable findings
during his clinical course. However, 1 month after the
admission, echocardiography detected vegetation on the
mitral valve, which was compatible with infectious endo-
carditis (Fig. 3, right panel), although there had been no
findings of vegetation at 2 years before the admission
(Fig. 3, left panel). Physical examination after the echo-
cardiography revealed Janeway’s lesions, although we did
not detect Osler’s nodes or Roth’s spots. Therefore, we
stopped the intravenous piperacillin therapy and started
treatment using intravenous ampicillin/sulbactam (1.5 g
every other day) and intravenous gentamicin (100 mgFig. 4 The patient’s clinical course. PIPC piperacillin, APBC ampicillin, SBT suevery other day). The patient’s clinical course was un-
eventful, and he was later discharged to our outpatient
clinic (Fig. 4).
Discussion
K. kristinae was first described as Micrococcus kristinae
in 1974 and was subsequently classified as Micrococcus
spp., which is now separated into Micrococcus, Nesteren-
konia, Kytococcus, Dermacoccus, and Kocuria [1, 2]. K.
kristinae is a strictly aerobic species that is commonly
identified among skin and oral flora [3]. Most physicians
consider Micrococcus spp. (including Kocuria) non-
pathogenic, and we initially assumed that the blood cul-
tures from the present case were negative for pathogeniclbactam, GM gentamicin, Hb hemoglobin, CRP C-reactive protein
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were caused by this species are gradually being pub-
lished. The clinical characteristics of the 28 reported
cases of K. kristinae infections are summarized in Tables
2 and 3 [4–16]. Most K. kristinae infections are reported
as infections in immunocompromised hosts or patients
with underlying malignancy, ESRD requiring dialysis,
diabetes mellitus, and prematurity. Although published
reports of K. kristinae infections are rare, the prevalence
of this infection, especially among immunocompromised
hosts, may be underestimated, as most physicians likely
do not consider this organism as a pathogen.
Patients who are receiving RRT often have infectious
diseases, although the identification of their causative
microorganism(s) and focus of infection are difficult to
accurately diagnose. Furthermore, patients who areTable 2 Demographic data, treatments, and outcomes for 28 patien
Case Antibiotic regimen
1 Meropenem + glycopeptide→ ciprofloxacin + clindamycin→ cathete
2 Levofloxacin
3 Ceftriaxone + ofloxacin
4 Azithromycin + ceftriaxone + vancomycin + oseltamivir→ vancomycin
oxacillin
5 Vancomycin→ teicoplanin→ oxacillin
6 Piperacillin/tazobactam→ ciprofloxacin
7 Oxacillin + vancomycin
8 Oxacillin
9 Tobramycin→ cefotaxime + tazobactam→ ciprofloxacin + teicoplanin
clavulanic acid
10 Cefazolin + cefepime
11 Ceftriaxone + vancomycin
12 Ceftriaxone +metronidazole→ sulbactam/ampicillin + gentamicin
13 No antibiotics
14 Dicloxacillin + vancomycin + levofloxacin






21 Vancomycin + ceftazidime
22 Vancomycin
23 Vancomycin + ceftazidime
24 Oxacillin + vancomycin
25 Vancomycin + cefotaxime
26 Vancomycin + cefotaxime
27 Vancomycin + piperacillin/tazobactam
28 Piperacillin→ ampicillin/sulbactam + gentamicin
TPN total parenteral nutrition, NA not availablereceiving RRT are frequently immunocompromised and
may have atypical infectious organisms that are consid-
ered normal bacterial flora in healthy individuals [17].
Among patients who are undergoing RRT, the host’s im-
munity may be compromised by uremia that interferes
with T cell and B cell function, macrophage phagocyt-
osis, and antigen presentation, which can increase the
risk of infection [17]. The population of patients with
ESRD who receive RRT has been increasing worldwide,
and this population included 314,180 Japanese patients
in December 2013 [18]. Furthermore, the number of pa-
tients with diabetes mellitus is increasing, and diabetic
nephropathy has recently become the leading cause
(43.8 %) of RRT in Japan [18]. Because ESRD and dia-
betes mellitus can both lead to an immunocompromised
status and increase susceptibility to unusual infections,ts with Kocuria kristinae infections
Course (days) TPN Outcome Ref. Year
r removal NA NA Recovery 4 2002
14 No Recovery 5 2005
16 NA Death 6 2008
+ clindamycin→ 42 Yes Recovery 7 2011
NA Yes Recovery 8 2011
NA Yes Recovery 8 2011
NA Yes Recovery 8 2011
NA Yes Recovery 8 2011
+ amoxicillin/ 24 No Recovery 9 2011
14 No Recovery 10 2011
14 Yes Recovery 11 2012
25 No Death 12 2013
No No Unknown 13 2013
21 No Recovery 14 2014
16 No Recovery 14 2014
10 NA Recovery 15 2014
7 NA Recovery 15 2014
7 NA Recovery 15 2014
14 NA Recovery 15 2014
5 NA Recovery 15 2014
10 Yes Recovery 16 2015
10 Yes Recovery 16 2015
10 Yes Recovery 16 2015
9 Yes Recovery 16 2015
12 Yes Recovery 16 2015
10 Yes Recovery 16 2015
10 No Recovery 16 2015
30 No Recovery Current 2015
Table 3 Clinical, demographic, and bacterial data from 28 patients with Kocuria kristinae infections
Case Age, year
(month)
Sex Country Underlying disease Isolation site Catheters Clinical presentation
1 51 F Italy Ovarian cancer, chemotherapy Blood, catheter
tip
CVC Febrile neutropenia, sepsis
2 56 M Hong
Kong
Gallstones Biliary fluid No Acute cholecystitis
3 68 M France MDS, acute myelogenous leukemia, tuberculosis,
chemotherapy
Blood CVC Sepsis
4 29 F USA Pregnancy, hyperemesis gravidarum Blood CVC Suppurative thrombosis
5 89 F Taiwan Post-resection ischemic bowel status, short bowel
syndrome
Blood CVC Endocarditis
6 37 F Taiwan Gastric cancer Blood CVC Bacteremia
7 2 M Taiwan Congenital short bowel syndrome,
hypogammaglobulinemia
Blood CVC Bacteremia
8 68 F Taiwan Gastric cancer Blood CVC Bacteremia
9 78 M Italy ESRD on CAPD Peritoneal fluid PDC Peritonitis
10 69 M China ESRD on CAPD Peritoneal fluid PDC Peritonitis
11 0 (4.0) F Turkey Prolonged diarrhea, severe failure to thrive Blood CVC Black hairy tongue, fever,
bacteremia
12 74 M Italy Diabetes mellitus Blood No Foot ulcer, endocarditis, sepsis
13 20 M India Urethral stricture Urine UC Malaise
14 20 F Mexico ESRD on HD Blood CVC Bacteremia
15 68 M Mexico ESRD on CAPD Peritoneal fluid PDC Peritonitis
16 65 M India Lung small cell carcinoma Sputum NA Leukocytosis (neutrophillia)
17 65 M India Carcinoma soft palate Sputum NA Leukocytosis (neutrophillia)
18 41 F India Carcinoma lip and gingival sulcus Sputum NA Leukocytosis (neutrophillia)
19 39 M India Squamous cell carcinoma of the buccal mucosa pus NA Leukocytosis (neutrophillia)
20 42 F India Ductal carcinoma of the breast pus NA Leukocytosis (neutrophillia)
21 0 (1.4) M Taiwan Prematurity Blood CVC Sepsis
22 0 (0.6) M Taiwan Prematurity Blood CVC Sepsis
23 0 (0.7) F Taiwan Prematurity Blood CVC Sepsis
24 0 (1.1) F Taiwan Prematurity Blood CVC Sepsis
25 0 (0.6) F Taiwan Prematurity Blood, catheter
tip
CVC Sepsis
26 0 (0.6) F Taiwan Prematurity Blood, catheter
tip
CVC Sepsis
27 0 (2.5) F Taiwan Leukemia Blood, catheter
tip
CVC Neutropenic fever
28 61 M Japan ESRD on HD, diabetes mellitus Blood No Septic arthritis, endocarditis
Age is presented as year (month)
Abbreviations: ESRD end-stage renal disease, CAPD chronic ambulatory peritoneal dialysis, HD hemodialysis, CVC central venous catheter, PDC peritoneal dialysis
catheter, UC urinary catheter
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susceptible to uncommon and usually non-pathogenic
microorganisms. However, Kocuria spp. infections are
rarely reported among patients with diabetes and RRT.
We speculate that there are two reasons for this
phenomenon. First, most physicians believe that Kocuria
spp., Micrococcus spp., and especially K. kristinae are
non-pathogenic and might not consider these organismsas potentially causative organisms, despite observing
positive culture results. Second, most Kocuria spp. and
Micrococcus spp. are sensitive to almost all antibiotics
(except ampicillin and erythromycin), and monotherapy
often results in good outcomes [19]. In this context,
Japanese investigators have reported that the causes of
fever of unknown origin (FUO) are infection (27.7 %),
non-infectious inflammatory disease (18.4 %), malignancy
Horino et al. Renal Replacement Therapy  (2016) 2:32 Page 8 of 9(10.2 %), other conditions (14.8 %), and unknown causes
(28.9 %) [20]. Thus, given the frequency of an unknown
cause of FUO, we usually use empirical antibiotics to treat
infections of unknown origin until culture results are
available. Therefore, it is possible that repeating cultures
will not identify the same microorganisms in each culture,
as the empirical antibiotics might cure the infection with-
out severe clinical events (e.g., sepsis) before the second
sample is collected. Interestingly, infection is the primary
cause of death among Japanese patients who are receiving
RRT (26.5 %) [19], and it is likely that the number of pa-
tients with diabetes and RRT is going to continue increas-
ing. Furthermore, the population of elderly Japanese
patients is also increasing, which will likely result in a lar-
ger number of immunocompromised hosts. Based on
these factors, it is possible that an increasing number of
patients may have underlying K. kristinae infection that is
not diagnosed until they develop severe complications,
such as bacteremia and endocarditis. Therefore, it may be
prudent to assess the pathogenic capacity of K. kristinae
and any other unusual microorganisms, even if an infec-
tion of unknown origin improves after antibiotic mono-
therapy in patients who are elderly, have diabetes, or are
receiving RRT. Moreover, clinicians should not underesti-
mate the importance of a positive culture result for K.
kristinae, as patients may experience repeated infections,
develop severe infectious complications, and possibly die
from this infection.
During recent years, many investigators have reviewed
the diagnostic value of FDG-PET-CT. Although FDG was
first developed to trace brain metabolism [21], FDG-PET-
CT has subsequently been recognized as an early diagnos-
tic tool that has high sensitivity for malignancies, such as
melanoma and cervical, lung, breast, gastrointestinal,
ovarian, and prostatic cancers [22]. Furthermore, recent
studies have found that FDG-PET-CT could detect the ex-
istence of inflammatory diseases and determine their se-
verity and extent [23]. Although contrast-enhanced CT
and/or MRI are performed for diagnosing and examining
malignancies, infections, and autoimmune diseases, the
use of contrast agents for these techniques is often contra-
indicated in patients with severe renal insufficiency, as
these agents increase the incidence of their adverse effects.
In contrast, FDG-PET-CT is considered safer and simpler
for dialysis patients, compared to contrast-enhanced CT
or MRI. Therefore, we suggest that FDG-PET-CT should
be used for diagnosing and evaluating dialysis patients if
the origin of their disease is unclear and that physicians
should not delay this diagnostic imaging, which can lead
to a poor prognosis.
Conclusions
We report the first case of K. kristinae septic arthritis
associated with infectious endocarditis in a chronichemodialysis patient with diabetes mellitus. We suggest
that physicians should consider the pathogenic potential
of K. kristinae, as it can cause fatal infections (e.g., septic
arthritis and infectious endocarditis) in immunocom-
promised patients or patients with diabetes and RRT.
We also suggest that FDG-PET-CT is a very useful and
safe diagnostic tool, which can help identify the focus of
inflammatory disorders in dialysis patients.Consent
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